Late complications of clinical clostridium histolyticum collagenase use in Dupuytren's disease.

<h4>Introduction</h4>While Dupuytren's disease can cause disabling contractures requiring open surgery, a less-invasive option using Clostridium Histolyticum collagenase (CHC) via percutaneous injection was recently reported. A recent prospective, randomized trial demonstrated few c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Warren M Rozen, Yasith Edirisinghe, John Crock
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/04002241ef1741cca7591f8fa249087b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:04002241ef1741cca7591f8fa249087b
record_format	dspace
spelling	oai:doaj.org-article:04002241ef1741cca7591f8fa249087b2021-11-18T07:08:22ZLate complications of clinical clostridium histolyticum collagenase use in Dupuytren's disease.1932-620310.1371/journal.pone.0043406https://doaj.org/article/04002241ef1741cca7591f8fa249087b2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22912868/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Introduction</h4>While Dupuytren's disease can cause disabling contractures requiring open surgery, a less-invasive option using Clostridium Histolyticum collagenase (CHC) via percutaneous injection was recently reported. A recent prospective, randomized trial demonstrated few complications during 90 days follow-up, however did not assess any longer term follow-up for these patients. Long-term outcomes in this setting have not been adequately reported, and the current manuscript aims to identify late complications from the clinical use of percutaneous CHC.<h4>Methods</h4>The current manuscript reports an extended 12-month follow-up for a cohort of twelve of patients enrolled in the original prospective, randomized trial, treated at a single institution. An analysis of complications requiring surgical intervention was undertaken.<h4>Results</h4>Two of twelve patients reported debilitating pain and triggering requiring surgical intervention. Extensive deep-tissue scarring and adhesions were identified, providing the first visual and qualitative analysis of the pathologic effects of CHC.<h4>Conclusion</h4>Late complications from CHC use can and have occurred, outside the follow-up period of the initial phase III trials. Longer term follow-up of such patients is thus essential, and further investigation and characterization of the late effects of CHC use is warranted.Warren M RozenYasith EdirisingheJohn CrockPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 8, p e43406 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Warren M Rozen Yasith Edirisinghe John Crock Late complications of clinical clostridium histolyticum collagenase use in Dupuytren's disease.
description	<h4>Introduction</h4>While Dupuytren's disease can cause disabling contractures requiring open surgery, a less-invasive option using Clostridium Histolyticum collagenase (CHC) via percutaneous injection was recently reported. A recent prospective, randomized trial demonstrated few complications during 90 days follow-up, however did not assess any longer term follow-up for these patients. Long-term outcomes in this setting have not been adequately reported, and the current manuscript aims to identify late complications from the clinical use of percutaneous CHC.<h4>Methods</h4>The current manuscript reports an extended 12-month follow-up for a cohort of twelve of patients enrolled in the original prospective, randomized trial, treated at a single institution. An analysis of complications requiring surgical intervention was undertaken.<h4>Results</h4>Two of twelve patients reported debilitating pain and triggering requiring surgical intervention. Extensive deep-tissue scarring and adhesions were identified, providing the first visual and qualitative analysis of the pathologic effects of CHC.<h4>Conclusion</h4>Late complications from CHC use can and have occurred, outside the follow-up period of the initial phase III trials. Longer term follow-up of such patients is thus essential, and further investigation and characterization of the late effects of CHC use is warranted.
format	article
author	Warren M Rozen Yasith Edirisinghe John Crock
author_facet	Warren M Rozen Yasith Edirisinghe John Crock
author_sort	Warren M Rozen
title	Late complications of clinical clostridium histolyticum collagenase use in Dupuytren's disease.
title_short	Late complications of clinical clostridium histolyticum collagenase use in Dupuytren's disease.
title_full	Late complications of clinical clostridium histolyticum collagenase use in Dupuytren's disease.
title_fullStr	Late complications of clinical clostridium histolyticum collagenase use in Dupuytren's disease.
title_full_unstemmed	Late complications of clinical clostridium histolyticum collagenase use in Dupuytren's disease.
title_sort	late complications of clinical clostridium histolyticum collagenase use in dupuytren's disease.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/04002241ef1741cca7591f8fa249087b
work_keys_str_mv	AT warrenmrozen latecomplicationsofclinicalclostridiumhistolyticumcollagenaseuseindupuytrensdisease AT yasithedirisinghe latecomplicationsofclinicalclostridiumhistolyticumcollagenaseuseindupuytrensdisease AT johncrock latecomplicationsofclinicalclostridiumhistolyticumcollagenaseuseindupuytrensdisease
_version_	1718423833512247296

Late complications of clinical clostridium histolyticum collagenase use in Dupuytren's disease.

Ejemplares similares